Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

Biotechnology

Kura Oncology

Troy Wilson 

Kate McElhone

Roger Bakale

Tanya Spektor

Michael Grieco

Matt Kelly

Jianbing Zhang

Hunkar Gunes

Harris S. Soifer

David Reed

Daniel Corum

Arlette Holland

Kelly Cannan- Kennerly

Brian Powl

Maureen Clancy

Peter Dorff

Kathleen Ford

Mollie Leoni

Stephen Dale

Tom Doyle

Pete De Spain

Teresa Bair

Francis Burrows

The Leadership Team at Kura Oncology drives strategic vision and operational oversight, ensuring alignment across clinical development, investor relations, legal, finance, and medical affairs. This team of senior executives collaborates to make pivotal decisions that advance the company’s mission to develop precision medicines targeting cancer’s key drivers.

Leadership Team

Clinical Research and Development

Leadership Team

About

Team members

Other teams at Kura Oncology

Clinical Research and Development

Leadership Team